@article{JTD31260,
author = {Umberto Malapelle and Antonio Rossi and Emilio Bria},
title = {Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {Suppl 15},
year = {2019},
keywords = {},
abstract = {Non-small cell lung cancer (NSCLC) represents the leading cause of death for cancer (1). In 2004, for the first time Lynch et al. demonstrated that a subgroup of NSCLC patients (10–15%), harboring somatic mutations in the epidermal growth factor receptor (EGFR) gene, showed sensitivity and clinical benefit to a novel class of drugs targeting the tyrosine kinase domain; the so called tyrosine kinase inhibitors (TKIs) (2).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/31260}
}